Akebia Therapeutics, Inc. (AKBA) Rating Reiterated by HC Wainwright

Akebia Therapeutics, Inc. (NASDAQ:AKBA)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued on Wednesday. They currently have a $24.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 58.63% from the company’s current price.

Several other research firms also recently weighed in on AKBA. Zacks Investment Research upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Mizuho restated a “buy” rating and issued a $24.00 price target on shares of Akebia Therapeutics in a research note on Thursday, November 9th. ValuEngine upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. BidaskClub upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $28.00 target price on shares of Akebia Therapeutics in a research note on Saturday, September 16th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $20.75.

Shares of Akebia Therapeutics (AKBA) opened at $15.13 on Wednesday. Akebia Therapeutics has a 52 week low of $7.78 and a 52 week high of $20.25.

Akebia Therapeutics (NASDAQ:AKBA) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.07. The company had revenue of $41.28 million for the quarter, compared to the consensus estimate of $34.00 million. Akebia Therapeutics had a negative return on equity of 198.85% and a negative net margin of 137.80%. equities analysts predict that Akebia Therapeutics will post -2.74 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/11/17/akebia-therapeutics-inc-akba-rating-reiterated-by-hc-wainwright.html.

In other Akebia Therapeutics news, SVP Michel Dahan sold 5,000 shares of the stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $19.30, for a total transaction of $96,500.00. Following the sale, the senior vice president now directly owns 97,224 shares in the company, valued at approximately $1,876,423.20. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last quarter, insiders have sold 7,586 shares of company stock worth $147,289. Company insiders own 7.95% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. SG Americas Securities LLC purchased a new position in shares of Akebia Therapeutics in the 2nd quarter worth $132,000. Macquarie Group Ltd. purchased a new position in shares of Akebia Therapeutics in the 3rd quarter worth $183,000. Legal & General Group Plc boosted its stake in shares of Akebia Therapeutics by 8.0% in the 2nd quarter. Legal & General Group Plc now owns 9,672 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 714 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in shares of Akebia Therapeutics in the 3rd quarter worth $200,000. Finally, Creative Planning boosted its stake in shares of Akebia Therapeutics by 2.9% in the 2nd quarter. Creative Planning now owns 10,650 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 300 shares during the last quarter. Institutional investors and hedge funds own 59.27% of the company’s stock.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

What are top analysts saying about Akebia Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Akebia Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit